Keytruda changes the rules for head and neck cancer patients

22 October 2018

Merck & Co (NYSE: MRK) has presented striking data in head and neck cancer which, in line with the theme of this year’s ESMO congress, demonstrate the growing breadth of indications in which immune modulation may be an effective strategy.

The positive efficacy and safety data for Merck’s immuno-oncology star Keytruda (pembrolizumab), tested in the KEYNOTE-048 study, will be game changing in a therapeutic area not previously known to be responsive to this kind of therapy.

People in the trial had recurrent or metastatic head and neck cancer, and were treated in the first-line setting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK